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Streptococcus pneumoniae is a leading cause of pneumonia worldwide. However, the bur-
den of pneumococcal pneumonia among adults in low- and middle-income countries is not
well described.
Methods
Data from 2008–2012 was analyzed from two surveillance sites in Guatemala to describe
the incidence of pneumococcal pneumonia in adults. A case of hospitalized pneumococcal
pneumonia was defined as a positive pneumococcal urinary antigen test or blood culture in
persons aged 18 years hospitalized with an acute respiratory infection (ARI).
Results
Among 1595 adults admitted with ARI, 1363 (82%) had either urine testing (n = 1286) or
blood culture (n = 338) performed. Of these, 188 (14%) had pneumococcal pneumonia,
including 173 detected by urine only, 8 by blood culture only, and 7 by both methods. Inci-
dence rates increased with age, with the lowest rate among 18–24 year-olds (2.75/100,000)
and the highest among65 year-olds (31.3/100,000). The adjusted incidence of hospital-
ized pneumococcal pneumonia was 18.6/100,000 overall, with in-hospital mortality of 5%.
Conclusions
An important burden of hospitalized pneumococcal pneumonia in adults was described,
particularly for the elderly. However, even adjusted rates likely underestimate the true bur-
den of pneumococcal pneumonia in the community. These data provide a baseline against
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which to measure the indirect effects of the 2013 introduction of the pneumococcal conju-
gate vaccine in children in Guatemala.
Introduction
Pneumonia is a leading cause of death worldwide, and Streptococcus pneumoniae is a primary
etiology [1–3]. The global burden of pneumococcal pneumonia among young children has
been well characterized, with the highest incidence of disease and death occurring in low- and
middle- income countries [4]. Sparse data are available for adults in developing countries,
despite older adults and those with chronic illness being at high risk for pneumococcal disease.
Estimates of the proportion of hospitalized adult pneumonia caused by pneumococcus have
ranged from 17% to 45% [5, 6]. However, determining the etiology of pneumonia is challeng-
ing since diagnostic tools have important limitations [7–9], and the most sensitive of these
tools are not typically available in resource-poor settings.
Evidence from high-income countries shows that vaccinating infants with pneumococcal
conjugate vaccine (PCV) can prevent pneumococcal disease in adults through herd protection
since vaccinated children are less likely to be colonized with and transmit S. pneumoniae [10–
12]. However, it is unknown whether similar indirect protection will occur in low- and middle-
income countries, given the greater force of transmission, poor underlying health status and
low vaccine coverage. In Guatemala, a 13-valent PCV (PCV13) was introduced in November
2012 for children1 year old. As a lower-middle income country not eligible for support from
the Global Alliance for Vaccination and Immunization [13], it is important to demonstrate the
impact of PCV13 introduction in this setting, including direct and indirect effects, in order to
justify investment in the vaccine and guide decisions about sustained use. This study describes
the incidence of hospitalized pneumococcal pneumonia in adults to provide insight into the
pre-PCV burden.
Materials and Methods
Study area and design
The International Emerging Infections Program, a collaboration between the Universidad del
Valle de Guatemala (Guatemala City, Guatemala), the United States Centers for Disease Con-
trol and Prevention (Atlanta, GA) and the Guatemalan Ministry of Public Health and Welfare
(Guatemala City, Guatemala), conducts active, hospitalized-based surveillance for acute respi-
ratory infections (ARI) in two sites in Guatemala, as has been described previously [14]. Briefly,
surveillance in the Department of Santa Rosa started in November 2007 and is conducted at
the only hospital in the department, the National Hospital of Cuilapa (elevation approximately
900 m). In Quetzaltenango, surveillance for hospitalized ARI began in February 2009 and is
conducted at the Western Regional Hospital (elevation approximately 2300 m), one of two
public hospitals in the department. Both surveillance hospitals provide free healthcare and
serve mostly low- and mid-income populations.
At the hospitals, trained surveillance nurses search daily in logbooks in the emergency
rooms and inpatient wards to identify patients with respiratory disease. Patients admitted to
surveillance hospitals with evidence of acute infection (e.g. fever, elevated white blood cell
count) and at least one sign or symptom of respiratory disease (e.g., cough or difficulty breath-
ing) were considered ARI cases (Table 1). Enrolled patients were interviewed about demo-
graphic, risk factor and health history information. Additional data were abstracted from the
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medical record. A study physician performed a respiratory physical examination on all patients
who met the case definition. When feasible, study nurses measured peripheral oxygen satura-
tion using a pulse oximeter with the patient off oxygen. Urine samples were collected from ARI
patients aged 18 and tested using BinaxNOW1 (Binax, Inc., Portland, Maine), a rapid
immunochromatographic test (ICT) that detects S. pneumoniae C polysaccharide antigen.
Nasopharyngeal and oropharyngeal (NP/OP) swabs were also collected and tested using a real-
time probe-hydrolysis (TaqMan1) real-time reverse transcription PCR (rRT-PCR) assay to
detect eight respiratory viruses (syncytial virus (RSV), human metapneumovirus, adenovirus,
human parainfluenza virus 1–3, influenza virus A and B). In addition, at the discretion of the
treating physician, patients may have had a blood culture and/or chest x-ray performed. For
study participants, chest x-rays were interpreted by a panel of Guatemalan radiologists using
an adaptation of World Health Organization guidelines for standardized interpretation of
pediatric chest X-rays in order to identify likely bacterial pneumonia [15].
Analysis
The analysis included enrolled ARI cases, aged18 years with either ICT or blood culture
results available. A case of pneumococcal pneumonia was defined as an ARI case with either a
positive ICT or a blood culture that grew S. pneumoniae. Data from January 2008 for Santa
Rosa and from February 2009 for Quetzaltenango, through December 2012 for both study
sites, were included in this analysis. Characteristics and outcomes of patients with pneumococ-
cal pneumonia were described.
The incidence rate of hospitalized pneumococcal pneumonia was estimated by year, age
group and study site. Denominators were the age-specific total populations of the municipali-
ties in the surveillance catchment area obtained from the 2002 national census adjusted for
population growth, accounting for an 11-month period of surveillance in Quetzaltenango in
2009 (data in S1 Dataset). Incidence estimates were restricted to cases residing in a surveillance
catchment area for which a healthcare utilization survey had been carried out when surveil-
lance was initiated at each site. The surveys found that among persons aged 5 years hospital-
ized with pneumonia or severe respiratory disease during the prior 12 months, 75% in Santa
Table 1. Case definition for acute respiratory infection (ARI)*, Guatemala, 2008–2012.
Signs of acute infection Signs or symptoms of respiratory
disease
Fever (38°C) Signs
Hypothermia (<35.5°C) Abnormal breath sounds
Abnormal white blood cell (WBC) count < 3000 or >11000/
mm3
Tachypnea (20/minute)








*ARI case definition: hospitalized patient with at least one sign of acute infection and at least one sign or
symptom of respiratory disease.
doi:10.1371/journal.pone.0140939.t001
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Rosa and 50% in Quetzaltenango reported being admitted to the surveillance hospital [14, 16,
17]. In order to adjust estimates of hospitalized pneumococcal pneumonia incidence for those
cases seeking care elsewhere, observed case counts were divided by 0.75 and 0.50 in Santa Rosa
and Quetzaltenango, respectively. The incidence was further adjusted to account for missing
test results and proportion of eligible patients enrolled, and these adjustments were made by
year. Case-patients residing outside the catchment area were included in the descriptive analy-
sis but were not included in incidence calculations. All analyses were performed in R (version
2.13.1).
Ethics
The protocol was approved by the institutional review boards of the Universidad del Valle de
Guatemala and the Centers for Disease Control and Prevention, and reviewed by the Guate-
mala Ministry of Public Health. Verbal consent was requested of patients in order to screen
them for eligibility. Written, informed consent was obtained from eligible patients willing to
participate.
Results
From January 1, 2008 through December 31, 2012, a total of 1786 hospitalized patients aged
18 years met the ARI case definition for possible inclusion at the two hospitals, and 1595
(89%) were enrolled (Fig 1). Among 1363 case-patients with blood culture or urine antigen
testing, 1025 (75%) were tested by urine antigen test only, 77 (6%) by blood culture only, and
261 (19%) by both methods. A total of 188 (14%) cases of laboratory-confirmed pneumococcal
pneumonia were detected.
More than one-third of pneumococcal pneumonia cases (n = 71, 38%) were aged 65
years, and slightly less than half (n = 88, 47%) were male (Table 2) (data in S2 Dataset). The
majority of patients (84%) resided in households where the average monthly income was less
than 1,000 Quetzals, (USD ~$130). Cough, reported in 92% of cases, was the most common
symptom, followed by difficulty breathing (84%). Reported fever (72%) was more common
than measured fever (43%); of note 29 (50%) of cases reported having taken antipyretics. The
most common physical finding was tachypnea (respiratory rate>20 breaths per minute)
(64%), and relatively few case-patients (11%) had rales, rhonchi or crackles on exam.
Consolidation or large effusion on chest x-rays was present in 65% of pneumococcal pneu-
monia cases (Table 2). A total of 53 (28%) cases had a respiratory virus detected from the NP/
OP swab and 7 (13%) had more than one virus present. The frequency of viral pathogens
detected was similar in those with no pneumococcal etiology detected (data not shown). Dura-
tion of hospitalization ranged from 1 to 80 days (median 7 days). Cases were severe enough to
warrant an admission to the intensive care unit for 19 (11%) of patients, and 10 (5%) patients
died; the median age of patients who died was 44 years (range 34 to 88 years).
Pneumococcal pneumonia cases occurred throughout the year, with no clear seasonal pat-
tern. The timing of peaks of pneumococcal pneumonia cases was similar to that of the peaks in
the total number of hospitalized ARI cases over the study period. However, the timing of the
peaks varied from year to year (Fig 2) (data in S3 Dataset).
Between 2008 and 2012 the observed incidence of hospitalized pneumococcal pneumonia
in the defined catchment area ranged from 5.9 to 11.7 cases per 100,000 people (Table 3) (data
in S1 and S2 Datasets). Incidence rates adjusted for proportion of population that seeks care at
surveillance hospitals in the catchment area, proportion enrolled and tested ranged from 15.3
to 23.1 cases per 100,000 people by site and year. The ranges of annual incidence rates found in
Santa Rosa and Quetzaltenango were similar. There was no clear trend in the observed
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incidence over time (Table 3), with the highest in 2009 in both Santa Rosa (11.7 cases per
100,000) and Quetzaltenango (10.0 cases per 100,000). Correlation was observed in annual
incidence rates between the sites, with the ranks of incidence rates by year matching exactly
between Santa Rosa and Quetzaltenango during 2009–2012. Incidence rates increased with
age, and the highest rate was observed among adults aged65 years (31.3 per 100,000). How-
ever, there was no clear trend in the proportion of hospitalized ARI cases with pneumococcal
pneumonia by age (Fig 3) (data in S1 Table).
Discussion
This large hospital-based study describes an important burden of hospitalized pneumococcal
pneumonia among adults in a middle-income, Latin American country, before PCV introduc-
tion in infants. The greatest burden of pneumococcal pneumonia was observed among those
65 years (31.3 per 100,000 persons per year), a pattern consistent with other published data
[18–22]. Nearly half of patients with pneumococcal pneumonia required hospitalization for a
week or more, with an overall mortality of 5%. Of note, the proportion of all ARI cases that
Fig 1. Ascertainment of pneumococcal pneumonia within hospital surveillance of acute respiratory infection (ARI), Guatemala, 2008–2012. Flow
diagram of patients included in this analysis.
doi:10.1371/journal.pone.0140939.g001
Pneumococcal Pneumonia in Guatemalan Adults
PLOS ONE | DOI:10.1371/journal.pone.0140939 October 21, 2015 5 / 14




18 to 39 55/188 (29)
40 to 64 62/188 (33)
 65 71/188 (38)
Male 88/188 (47)
Quetzaltenango 101/188 (54)
Santa Rosa 87/188 (46)
Risk factors
Current smoker 35/186 (19)
Secondhand smoke exposure 28/186 (15)
One or more comorbidities 68/185 (37)
Chronic respiratory disease^ 31/184 (17)
Diabetes 21/183 (11)
Chronic cardiovascular disease^^ 30/185 (16)
Socioeconomic status
Monthly family income < USD $130 140/166 (84)
Overcrowding ( 3 persons per bedroom) 54/186 (29)
Electricity in home 166/186 (89)
Dirt floor 61/186 (33)
Completed primary school 22/186 (12)
Completed high school 10/186 (5)
Signs, symptoms and physical exam findings
Cough 170/185 (92)
Difficulty breathing 155/185 (84)
Reported fever 135/187 (72)
Measured fever  38°C 80/187 (43)
Tachypnea ( 20 breaths/min) 117/182 (64)
Hypoxemia† 71/163 (44)
Rales, crackles or rhonchi on lung exam 20/182 (11)
Wheezing on lung exam 53/182 (29)
Testing results
Abnormal white blood cell count <3000/mm3 3/185 (2)
Abnormal white blood cell count >11000/mm3 114/185 (62)
Consolidation or large effusion on chest x-rays 80/123 (65)
Detection of other respiratory viruses
Respiratory syncytial virus 8/186 (4)
Human metapneumovirus 7/186 (4)
Parainfluenza virus 1, 2, or 3 13/186 (7)
Adenovirus 11/186 (6)
Influenza virus A or B 20/186 (11)
Outcome
Intensive care unit 19/180 (11)
Mechanical ventilation 15/180 (8)
Hospitalized  1 week 86/182 (47)
(Continued)
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tested positive for S. pneumoniae did not vary widely by age, suggesting that while elderly are at
high risk for pneumococcal disease, they are also at high risk for other causes of pneumonia.
Overall in this study 14% of adults hospitalized with an acute respiratory infection had a
pneumococcal etiology. A study conducted in Nicaragua that relied primarily upon urine anti-
gen tests to diagnose pneumococcal pneumonia similarly found that 17% of adult community
acquired pneumonia was attributable to pneumococcus [23]. Our findings are also consistent
with studies from Asia [24] and Africa [25] that have used urine antigen test to diagnose adult
pneumococcal pneumonia. However, with a sensitivity of approximately 60–80% and a speci-
ficity of 83–97% for pneumococcal pneumonia [3, 9, 26, 27], urine antigen testing likely under-
estimates the true proportion of pneumonia caused by S. pneumoniae. Studies relying only on
blood culture will greatly underestimate the contribution of pneumococcus [28]. A study from
Kenya using latent class analysis, a statistical method for estimating disease burden despite the
lack of a gold standard test, estimated that nearly half of adult community acquired pneumonia
may be caused by pneumococcus [7]. This suggests that our study underestimates the burden
of hospitalized pneumococcal pneumonia even though both blood culture and urine antigen
test were performed. Improved diagnostic tools would help establish more accurate and robust
estimates of pneumococcal pneumonia burden among adults globally.
Data on the incidence of adult pneumococcal pneumonia from developing countries are
extremely limited. A study in two provinces in rural Thailand found an adjusted overall inci-
dence rate of hospitalized pneumococcal pneumonia among persons aged 18 years or older to
be 24 per 100,000 person-years [29], which is relatively similar to the rates we observed (18.6
per 100,000). In contrast a study in rural western Kenya using relatively similar methods
reported markedly higher rates of pneumococcal pneumonia among adults: 520 per 100,000
among human immunodeficiency virus (HIV)-uninfected, and 6710 per 100,000 among those
infected with HIV [30], which is a strong risk factor for pneumococcal disease [31, 32].
Although an important difference is that the Kenyan study includes pneumococcal pneumonia
outpatients (53%), the rates are still an order of magnitude higher than our study even after
excluding outpatients. In addition to HIV, other risk factors for pneumococcal pneumonia,
such as those associated with poverty [33], may explain some of the variability observed across
regions. The rates of pneumococcal pneumonia that were observed in Guatemala are slightly
higher than those reported by the Etiology of Pneumonia in the Community study in the US
(12 per 100,000 adults per year) [22]. The vast difference in incidence estimates across sites
highlights the need for more population-based studies of adult pneumococcal burden, particu-
larly in resource-poor settings.
No clear seasonal pattern for pneumococcal disease was observed. In temperate regions,
pneumococcal infection rates increase during the winter months and decline in the summer
[31, 34], a pattern that is likely impacted by peaks in viral infections [35]. In Guatemala, RSV
burden is greatest from July to November, and influenza A virus cases occur most frequently
fromMarch to July [14, 36, 37]; these non-overlapping peaks may make it harder to observe
Table 2. (Continued)
n/N (%)
Death (in hospital) 10/183 (5)
^ Includes asthma or lung disease
^^ Includes cardiovascular disease or hypertension
† Oxygen saturation <90% in Santa Rosa and <88% in Quetzaltenango, adjusted for elevation
doi:10.1371/journal.pone.0140939.t002
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associations between increases in pneumococcal pneumonia and increases in viral infections. It
has been described that respiratory viruses predispose to secondary bacterial infections, and
there is evidence that influenza virus alters the host in a way that predisposes to adherence,
invasion and induction of disease by pneumococcus [38–40]. Among adults with pneumococ-
cal pneumonia in this study, 28% had at least one virus detected, and 11% had concurrent
influenza infection, suggesting that achieving better control of influenza in adults in Guatemala
could potentially reduce the burden of pneumococcal disease. Since 2007, influenza vaccination
has been recommended for adults aged60 years in Guatemala, although coverage has
remained low.
PCV13 was introduced in the infant immunization program in Guatemala in November
2012 [41]. At this time, PAHO does not recommend the use of PCV for adults [42]. In the
USA and in almost all European countries, policies to vaccinate elderly and ´at risk´ adults for
the 23-valent pneumococcal polysaccharide vaccine (PPSV23) have been in place for more
than two decades [43]. In August 2014, the Advisory Committee on Immunization Practices
Fig 2. Number of hospitalized ARI tested and pneumococcal pneumonia cases bymonth, Guatemala, 2008–2012*. Pneumococcal pneumonia cases
detected by urine antigen test or blood culture.
doi:10.1371/journal.pone.0140939.g002
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(ACIP)recommended that both PCV13 an PPSV23 be routinely administered in series to all
adults65 years [44]. Indirect protection against invasive pneumococcal disease [12, 45, 46]
and pneumonia [11, 12, 47, 48] in adults has been reported from high-income settings follow-
ing PCV introduction for infants. The development of herd effects in resource-poor settings
may be affected by higher rates of pneumococcal carriage, the force of transmission of S. pneu-
moniae from children to adults (related to crowding, exposure to indoor air pollution, sanita-
tion/hygiene), the robustness of the immune response in vaccinated children (which may be
affected by chronic conditions such as malnutrition), and vaccine coverage. Herd protection
can dramatically alter cost-effectiveness analyses of PCV [49, 50]; for a middle-income country
such as Guatemala, the additional benefit of preventing adult pneumonia can have tremendous
policy relevance. These data can be used as a baseline to provide that evidence.
The findings of this study are subject to several limitations. Blood cultures are not routinely
used for ARI patients and only detect bacteremic cases that are not already on antibiotic treat-
ment [8, 51, 52]. Urine antigen testing can detect non-bacteremic pneumococcal pneumonia in
adults, yet with a suboptimal sensitivity [3, 9, 26, 27], so some cases will be missed. Use of
newer, more sensitive urine antigen assays could provide a more accurate estimation of pneu-
mococcal disease burden in adults [5, 6, 53, 54]. Our surveillance is hospital-based; the findings
cannot be extrapolated to persons with ARI that seek care elsewhere or do not seek medical
care. In estimating the incidence of hospitalized pneumococcal pneumonia, we attempted to
adjust for lack of testing, non-enrollment and proportion of population that seeks care at sur-
veillance hospitals; however the proportion seeking care at surveillance hospitals may have
changed over time, which would affect the observed and adjusted incidence. This study only
estimates the incidence of hospitalized pneumococcal pneumonia, and failure to account for
non-hospitalized cases may have resulted in underestimation of the true burden of pneumo-
coccal pneumonia in adults.
Despite the limitations, our findings provide insight into the burden of hospitalized pneu-
mococcal pneumonia in adults. Information on burden of pneumonia is essential for evidence-
based public health policies and can guide decisions about the use of prevention interventions
such as vaccines. These data provide a baseline against which to measure the indirect effects of
the recent introduction of PCV in Guatemala.
Table 3. Observed and adjusted incidence rates of pneumococcal pneumonia cases, Guatemala, 2008–2012.
Department Year Cases Population Observed incidence per 100,000 Adjusted incidences* per 100,00
Santa Rosa 2008 9 125396 7.2 15.3
2009 15 128536 11.7 19.1
2010 13 131928 9.9 17.7
2011 15 135338 11.1 18.1
2012 10 138766 7.2 16.7
Quetzaltenango 2009 17 170822 10.0 23.1
2010 14 192193 7.3 16.9
2011 17 198202 8.6 22.6
2012 12 204381 5.9 16.4
Overall 122 1425562 8.6 18.6
* Adjusted for proportions of cases with test results (64%-95%), eligible patients enrolled (81%-98%) and proportion of population that seeks care at
surveillance hospitals (50%-75%) (adjustment factors in S2 Table).
doi:10.1371/journal.pone.0140939.t003
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Supporting Information
S1 Dataset. Population. Number people living in the pneumonia surveillance catchment area
by department and year.
(XLSX)
S2 Dataset. Pneumococcal pneumonia patients. Clinical characteristics of individual patients
with pneumococcal pneumonia.
(XLSX)
S3 Dataset. ARI and pneumococcal pneumonia cases by year.Weekly numbers of ARI and
pneumococcal pneumonia cases.
(XLSX)
Fig 3. Hospitalized pneumococcal pneumonia incidence rates and proportion of acute respiratory infection (ARI) cases by age, Guatemala, 2008–
2012. Incidence rates (bars) ranged from 2.75/100,000 (among 18–24 year-olds) to as high as 31.3 per 100,000 (among adults aged65 years). Proportion
of ARI positive for pneumococcus (line) was more stable than the incidence rate across age groups.
doi:10.1371/journal.pone.0140939.g003
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S1 Table. ARI and pneumococcal pneumonia by age group. Number of ARI and pneumo-
coccal pneumonia cases by age group.
(XLSX)
S2 Table. Factors for incidence rate adjustments. Factors used to adjust the incidences
according to department, year and type of adjustment.
(XLSX)
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